[go: up one dir, main page]

ECSP13012709A - Respuesta inmune potenciada en la especie bovina - Google Patents

Respuesta inmune potenciada en la especie bovina

Info

Publication number
ECSP13012709A
ECSP13012709A ECSP13012709A ECSP13012709A EC SP13012709 A ECSP13012709 A EC SP13012709A EC SP13012709 A ECSP13012709 A EC SP13012709A EC SP13012709 A ECSP13012709 A EC SP13012709A
Authority
EC
Ecuador
Prior art keywords
bovine species
immune response
potentiated
response potentiated
bovine
Prior art date
Application number
Other languages
English (en)
Inventor
Albert Abraham
Daniel Keil
Jason Nickell
Christian Weiss
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of ECSP13012709A publication Critical patent/ECSP13012709A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un procedimiento de activación inmune que es efectivo para provocar una respuesta inmune no específica para antígenos en un miembro de la especie bovina. El procedimiento es particularmente efectivo para proteger un miembro de la especie bovina de enfermedades infecciosas y tratar animales afectados de una enfermedad infecciosa.
ECSP13012709 2010-12-22 2013-06-21 Respuesta inmune potenciada en la especie bovina ECSP13012709A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061426255P 2010-12-22 2010-12-22

Publications (1)

Publication Number Publication Date
ECSP13012709A true ECSP13012709A (es) 2013-08-30

Family

ID=45444595

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012709 ECSP13012709A (es) 2010-12-22 2013-06-21 Respuesta inmune potenciada en la especie bovina

Country Status (35)

Country Link
US (3) US20130295167A1 (es)
EP (1) EP2654785B1 (es)
JP (2) JP6058550B2 (es)
KR (1) KR101940826B1 (es)
CN (2) CN103501810A (es)
AR (1) AR084510A1 (es)
AU (1) AU2011347464B2 (es)
BR (1) BR112013016231B1 (es)
CA (1) CA2822359C (es)
CL (1) CL2013001833A1 (es)
CO (1) CO6761354A2 (es)
CR (1) CR20130312A (es)
DK (1) DK2654785T3 (es)
DO (1) DOP2013000149A (es)
EC (1) ECSP13012709A (es)
ES (1) ES2722204T3 (es)
GT (1) GT201300168A (es)
HK (1) HK1259341A1 (es)
HR (1) HRP20190779T1 (es)
HU (1) HUE043473T4 (es)
IL (1) IL226733B (es)
LT (1) LT2654785T (es)
MX (1) MX345854B (es)
MY (1) MY167159A (es)
NZ (1) NZ612285A (es)
PH (1) PH12013501348B1 (es)
PL (1) PL2654785T3 (es)
PT (1) PT2654785T (es)
RU (1) RU2606855C2 (es)
SI (1) SI2654785T1 (es)
TR (1) TR201906323T4 (es)
TW (1) TWI587877B (es)
UA (1) UA118537C2 (es)
UY (1) UY33821A (es)
WO (1) WO2012084951A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013016231B1 (pt) 2010-12-22 2021-03-23 Bayer Intellectual Property Gmbh Composição imunomoduladora para o tratamento de doença respiratória bovina
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
CA2940794C (en) * 2014-02-28 2022-05-31 Bayer Animal Health Gmbh Immunostimulatory plasmids
CN104825393B (zh) * 2015-01-16 2017-11-10 艾美科健（中国）生物医药有限公司 一种硫酸头孢喹肟肺靶向脂质体制剂及其制备方法
WO2016207314A2 (en) * 2015-06-26 2016-12-29 Bayer Animal Health Gmbh Methods of modulating cytosolic dna surveillance molecules
EP3328423B1 (en) * 2015-07-31 2021-05-26 Bayer Animal Health GmbH Enhanced immune response in fish
AU2016302436B2 (en) * 2015-07-31 2022-03-03 Elanco Animal Health Gmbh Enhanced immune response in porcine species
AU2017301528A1 (en) * 2016-07-26 2019-02-14 Elanco Animal Health Gmbh Increased fertility in bovine species
KR102069670B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
US11932857B2 (en) 2017-12-15 2024-03-19 Elanco Animal Health Gmbh Immunostimulatory oligonucleotides
CN108812546A (zh) * 2018-09-07 2018-11-16 四川省草原科学研究院 适于青藏高原地区牦牛运输减少应激的药物及使用方法
CN109646435B (zh) * 2019-01-11 2021-08-03 山东省农业科学院奶牛研究中心 厄他培南钠在制备防治牛传染性鼻气管炎药物中的应用
US11689594B2 (en) 2019-03-28 2023-06-27 Nec Corporation Information processing apparatus, server allocation apparatus, method, and computer readable medium
CN114480663A (zh) * 2021-11-15 2022-05-13 贵州省畜牧兽医研究所 用于检测猪源差异脲原体的引物对、试剂盒及检测方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5427791A (en) 1992-08-05 1995-06-27 Regents Of The University Of Minnesota Embryonal vaccine against Newcastle disease
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5830878A (en) * 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6048535A (en) 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US6586409B1 (en) 1999-03-26 2003-07-01 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
RU2158587C1 (ru) * 1999-05-11 2000-11-10 Ставропольское научно-производственное объединение "Пульс" Антибактериальное средство для лечения заболеваний сельскохозяйственных животных и птиц, способ профилактики и лечения цыплят при заболеваниях бактериальной этиологии, способ лечения респираторной болезни телят бактериальной этиологии, способ профилактики туберкулеза у крупного рогатого скота
US20040002472A1 (en) * 2000-01-21 2004-01-01 Audonnet Jean-Christophe Francis Vaccination or immunization using a prime-boost regimen
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
RU2274643C2 (ru) 2001-04-24 2006-04-20 Иннодженетикс Н.В. Выделенный оболочечный белок hcv, способ его получения и лекарство, вакцина, фармацевтическая композиция (варианты) его содержащие
MXPA03011924A (es) * 2001-07-02 2004-03-26 Pfizer Prod Inc Vacuna de micoplasma hyopneumoniae y metodos para reducir la neumonia por mycoplasma bovis en el ganado.
PL1605971T3 (pl) * 2003-03-26 2010-10-29 Wyeth Llc Kompozycja immunogenna i sposoby
TW200505425A (en) * 2003-05-29 2005-02-16 Schering Plough Ltd Compositions and method for treating infection in cattle and swine
JP2007509040A (ja) * 2003-10-11 2007-04-12 イネックス ファーマシューティカルズ コーポレイション 先天性免疫及び抗体依存性細胞傷害を強化するための方法及び組成物
UY29915A1 (es) 2005-11-15 2007-06-29 Boehringer Ingelheim Vetmed Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
JP2008094763A (ja) * 2006-10-12 2008-04-24 Takeshi Ogura 海洋ミネラル成分からなるインターフェロンγ産生増強剤
EP2249843A4 (en) * 2008-02-24 2013-05-08 Us Gov Health & Human Serv USE OF IMMUNOGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF INFECTIONS BY DISEASES
JP5759890B2 (ja) * 2008-03-25 2015-08-05 ジュバリス・バイオセラピューティクス・インコーポレイテッドＪｕｖａｒｉｓ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． カチオン性脂質−ｄｎａ複合体（ｃｌｄｃ）の投与による免疫応答の増強
WO2010051210A1 (en) * 2008-10-31 2010-05-06 Boehringer Ingelheim Vetmedica, Inc. Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
MX336019B (es) * 2009-05-14 2016-01-06 Bayer Ip Gmbh Respuesta inmunitaria reforzada en especies aviares.
BR112013016231B1 (pt) * 2010-12-22 2021-03-23 Bayer Intellectual Property Gmbh Composição imunomoduladora para o tratamento de doença respiratória bovina

Also Published As

Publication number Publication date
NZ612285A (en) 2015-09-25
SI2654785T1 (sl) 2019-06-28
RU2606855C2 (ru) 2017-01-10
KR20130132926A (ko) 2013-12-05
AU2011347464A2 (en) 2013-08-22
MY167159A (en) 2018-08-13
HRP20190779T1 (hr) 2019-06-28
GT201300168A (es) 2015-02-23
AU2011347464B2 (en) 2016-08-25
CO6761354A2 (es) 2013-09-30
BR112013016231A2 (pt) 2016-09-27
UA118537C2 (uk) 2019-02-11
MX2013007064A (es) 2013-08-21
US20130295167A1 (en) 2013-11-07
HK1259341A1 (zh) 2019-11-29
CN108379576A (zh) 2018-08-10
CA2822359C (en) 2021-06-01
EP2654785B1 (en) 2019-03-20
HUE043473T2 (hu) 2019-08-28
DOP2013000149A (es) 2013-08-15
RU2013133730A (ru) 2015-01-27
JP2017036290A (ja) 2017-02-16
TWI587877B (zh) 2017-06-21
EP2654785A1 (en) 2013-10-30
CN103501810A (zh) 2014-01-08
BR112013016231B1 (pt) 2021-03-23
TW201306877A (zh) 2013-02-16
DK2654785T3 (da) 2019-06-24
WO2012084951A1 (en) 2012-06-28
CL2013001833A1 (es) 2014-06-20
JP6058550B2 (ja) 2017-01-11
LT2654785T (lt) 2019-07-10
US20190201434A1 (en) 2019-07-04
IL226733B (en) 2020-06-30
TR201906323T4 (tr) 2019-05-21
UY33821A (es) 2012-07-31
KR101940826B1 (ko) 2019-01-21
PT2654785T (pt) 2019-06-25
PH12013501348B1 (en) 2019-11-22
JP2014500292A (ja) 2014-01-09
US20140010865A1 (en) 2014-01-09
MX345854B (es) 2017-02-17
ES2722204T3 (es) 2019-08-08
CA2822359A1 (en) 2012-06-28
AU2011347464A1 (en) 2013-07-11
PL2654785T3 (pl) 2019-09-30
US10751361B2 (en) 2020-08-25
HUE043473T4 (hu) 2019-12-30
CR20130312A (es) 2013-10-17
PH12013501348A1 (en) 2013-08-28
AR084510A1 (es) 2013-05-22

Similar Documents

Publication Publication Date Title
ECSP13012709A (es) Respuesta inmune potenciada en la especie bovina
ECSP11011448A (es) Respuesta inmunitaria reforzada en especies aviares
MX389274B (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano.
ECSP14000329A (es) Moléculas que son anticuerpos con especificidad por ox40 humano
CR20120404A (es) Proteinas de enlace cd127
UY34995A (es) Formulaciones de anticuerpo y proteína
GT201200318A (es) Anticuerpos hacia gdf8 humano
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
MX346450B (es) Composiciones y métodos para el tratamiento de la enfermedad celíaca.
EP2975055A4 (en) C5 ANTIBODIES AND METHOD FOR PREVENTING AND TREATING COMPLEMENT-MEDIATED ILLNESSES
CO2018001840A2 (es) Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5
BR112014020019A8 (pt) vetores poxvirais recombinantes expressando tanto proteínas da raiva e ox40 e vacinas feitas a partir destes
ECSP13012673A (es) Métodos y composiciones para inmunoterapia para enfermedad neural
CO2018002207A2 (es) Composiciones contra alergia a los gatos
IN2014CN04071A (es)
MX2014013678A (es) Agentes para neutralizacion de influenza.
MX381211B (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
MX2017000869A (es) Vacuna emulsionada para obtener formulaciones de inmunoglobulinas igy concentradas; procesos y usos de las mismas.
CO2019001112A2 (es) Anticuerpos con inmunogenicidad baja y usos de estos referencia cruzada a solicitudes relacionadas
MX2014006248A (es) Anticuerpos nonoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs).
CL2012002654A1 (es) Compuesto de propilmetilfenol o una composicion que lo comprende para tratar septicemia rickettsial salmonidea (srs) y/o enfermedades causadas por la piscirickettsia salmonis.
NI201300058A (es) Respuesta inmune potenciada en la especie bovina
BR112015028986A2 (pt) métodos para produzir partículas compreendendo proteínas terapêuticas
BR112012022680A2 (pt) métodos para proteger um animal um canino contra doença, e, uso de uma vacina contra vírus da influenza canina
NZ629420A (en) Sheep nematode vaccine